Boehringer Ingelheim announced results from a phase III study, confirming that Cyltezo® is equivalent to Humira®*, with no clinically meaningful differences in efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis.    “This phase III study builds on recent evidence that demonstrates Cyltezo® is equivalent to Humira® for the treatment of moderately-to-severely active rheumatoid arthritis,” said Key Tetzlaff, vice president and medical h...